Literature DB >> 793563

Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report.

D R Wood, F W Reimherr, P H Wender, G E Johnson.   

Abstract

Minimal brain dysfunction (MBD) has long been considered a disorder limited to childhood. A number of longitudinal and adoption studies suggest that MBD may persist into adult life where its existence is concealed by the application of a variety of diagnostic labels. In order to test the hypothesis that MBD does persist into adulthood, 15 putative MBD adults were identified on the basis of current MBD-like complaints, self-description of MBD characteristics in childhood, and a parental rating (on a standardized form) of "hyperactivity" in childhood. Eleven of the 15 subjects were given a double-blind trial of methylphenidate hydrochloride, and all 15 were given an open trial of pemoline, imipramine hydrochloride, or amitryptiline hydrochloride. Eight of the 11 showed a significant response to the double-blind trial of methylphenidate. Of the 15, eight showed a good response to stimulants or tricyclic antidepressants, two showed a moderately favorable response, and five were unresponsive to drug therapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 793563     DOI: 10.1001/archpsyc.1976.01770120057005

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  27 in total

Review 1.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

2.  Psychiatry-epitomes of progress: hyperkinetic behavior disorder.

Authors:  J H Satterfield
Journal:  West J Med       Date:  1981-02

Review 3.  Cognitive impairments in abstinent alcoholics.

Authors:  G Fein; L Bachman; S Fisher; L Davenport
Journal:  West J Med       Date:  1990-05

4.  Methylphenidate-induced improvements of various measures of attention in adults with attention deficit hyperactivity disorder.

Authors:  O Tucha; L Mecklinger; R Laufkötter; H E Klein; S Walitza; K W Lange
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

5.  Premorbid prevalence of poor academic performance in severe head injury.

Authors:  J F Haas; D N Cope; K Hall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-01       Impact factor: 10.154

6.  Benzodiazepines in the treatment of depressive, borderline personality, and schizophrenic disorders.

Authors:  A F Schatzberg; J O Cole
Journal:  Br J Clin Pharmacol       Date:  1981       Impact factor: 4.335

Review 7.  Current issues in the diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder.

Authors:  Paul J Frick; Joel T Nigg
Journal:  Annu Rev Clin Psychol       Date:  2011-12-21       Impact factor: 18.561

Review 8.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

9.  Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.

Authors:  Suma M Krishnan; Michael Pennick; Jeffrey G Stark
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 10.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.